Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Ainos, Inc.

$2.16

+0.28 (+14.89%)

D 37Pipeline Score Overvalued Biotech · Clinical
Market Cap
20.12 M
EPS
-2.90
P/E Ratio
-0.81 $
Value Trade
108.26 K
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • Revenue

    161.00

  • R&D Expenses

    1.69 M

  • Operating CF

    -983.42 K

  • Total Assets

    22.08 M

  • Total Liabilities

    16.39 M

  • Equity

    5.69 M

  • D/E Ratio

    12,345

0.49 %
Week
17.39 %
1 Month
41.62 %
3 Month
47.39 %
6 Month
-95.18 %
5 Year
-99.99 %
All Time
Cash Data
Caution

  • Cash Position

    2.84 M

  • Monthly Burn

    328.00 K

  • Runway

    7.8 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 13, 2026
Overview
Volume
25.49 K
52 Week Range
1.26 - 4.50
% held by Insiders
75.2 %
% held by Institutions
1.56 %
Enterprise Value
31.09 M
Total Shares
4.82 M
Short %
4.35 %
Float Shares
250.74 K
Company Description
HQ: 3050 POST OAK BLVD,, HOUSTON, ...
Founded:1984
Employees:41
https://www.ainos.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D37
Pipeline Score
$11M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.5x
rNPV / MCap
Top 52%
Micro Cap
(rank 435 of 905)
Percentile Rank
Ainos, Inc. faces pipeline headwinds (37/100), with $1.8B risk-adjusted pipeline value, led by Interferon alpha lozenge in Respiratory Tract Diseases (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Interferon alpha lozenge
Small molecule		Respiratory Tract DiseasesPhase 2NCT0144277914% $1.1B COMPLETED 18 - -May 1, 2007 -Apr 20, 2012
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in AIMD
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Ainos, Inc. (AIMD) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
AIMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AIMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AIMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
AIMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
AIMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How AIMD ranks across every disease it competes in
Competitive Position is a premium feature
See how AIMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial